Martin Brischwein

Papers

Total Citations

H-Index

About

Martin Brischwein is a pioneering figure in the development of sensor-based platforms for real-time monitoring of living cells and tissues, with a primary focus on advancing personalized cancer chemotherapy. His research bridges bioengineering and oncology, creating automated systems that enable controlled, non-invasive assays of cellular responses to therapeutic agents. Brischwein’s most-cited work, "Automated platform for sensor-based monitoring and controlled assays of living cells and tissues" (2013, 26 citations), established a foundational tool for dynamic, high-content screening of cell behavior. Expanding on this, his 2012 study on "Sensor-based cell and tissue screening for personalized cancer chemotherapy" (24 citations) demonstrated how these platforms could tailor drug efficacy testing to individual patient tumor samples, reducing trial-and-error in treatment. Though citation counts are modest, the translational impact of his work is significant, offering a path toward more precise, patient-specific oncology. Brischwein’s contributions have been instrumental in integrating microsensors with cell culture systems, enabling continuous, label-free monitoring of metabolic and morphological changes—a critical step toward replacing traditional endpoint assays. His research continues to inspire innovations in lab-on-a-chip technologies for personalized medicine.